A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

ETCTN-8282 study team

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds